Navigation Links
Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Date:2/28/2008

MONTVALE, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today reported net earnings of $128.4 million, or $1.18 per share, for the year ended December 31, 2007 on revenues of $2.5 billion. On a non-GAAP basis, adjusted earnings per share were $3.16 for 2007. A reconciliation of GAAP-based earnings per share to adjusted earnings per share is presented in the table at the end of this press release. For the fourth quarter ended December 31, 2007, net earnings were $32.5 million, or $0.30 per share, on revenues of $668.7 million. On a non-GAAP basis, adjusted earnings per share were $0.79 for the quarter.

In the fourth quarter of calendar 2006, Barr changed its fiscal year end from June 30th to December 31st, effective December 31, 2006. In addition, on October 24, 2006, Barr acquired PLIVA d.d., a Croatian generics pharmaceutical company, for approximately $2.4 billion. As a result of these two events, the comparison of information for the year ended December 31, 2007 and the 12- month period ended December 31, 2006, which is unaudited, is not very meaningful. In this release, "2007" refers to Barr's calendar year ended December 31, 2007, and "2006" refers to the 12-month period ended December 31, 2006 and includes PLIVA's results from October 25, 2006 through December 31, 2006.

"I am pleased to report strong revenue growth across the Company in 2007, driven by proprietary and U.S. generic sales, as well as sound results in our international markets. In addition, during the year we invested a record $248 million in new product development, and filed a record 30 ANDAs and three NDAs in the United States. These are exceptional results for our Company, particularly given that significant management
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... 2014 Women in the West ... an additional family planning option. Sayana® Press has ... all levels of the health system and in ... widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the ... the first of four African countries expected to ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., ... the relaunch of his highly informative blog, now named Stem ... What are Stem Cells ?” Dr. Harman’s purpose for ... the basics of stem cell therapy so that pet owners ... treatment when considering regenerative medicine. , A veterinarian by trade, ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... today the establishment of a collaboration with Ono ... and development of small molecule modulators of an ... terms of the agreement, Receptos will use its ... crystal structures of the discovery target and drive ...
... , Inc ... called Zybodies™, announced today that it has promoted ... and appointed Daniel L. Menichella as Chief Business ... in September 2009, Zyngenia has made tremendous progress in both developing ...
... NEW YORK, Dec. 12, 2011  Fox Insurance Company, a ... NY, announces a judgment in the arbitration between the ... excess of $3.3 million, following a suit against ProCare ... contract.  Nathan M. Barotz, chairman of ...
Cached Biology Technology:Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research 2Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research 3Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 2Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 3Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager 2
(Date:7/11/2014)... The Chinese University of Hong Kong, BGI and other ... to salt tolerance, with implication for improving this important ... online in Nature Communications provides an effective ... , Soybean is an important crop for the world. ... less genetic diversities than their wild counterparts. Among the ...
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... kidney injury related to the use of hydroxyethyl starch ... molecules, according to a report in Anesthesia & ... Society (IARS). , The "total mass of HES molecules" ... renal proximal tubule cells (PTCs), concludes the laboratory study ... Wrzburg, Austria. Other factorssuch as differences in the ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... day of competition in London, a team of four ... emerged as the winners of this year,s Biotechnology Young ... Biotechnology Young Entrepreneurs Scheme (YES) competition are Ben Owens, ... University of Oxford. The team pitched their ...
... -- The International Center for Tropical Agriculture (CIAT) ... a collaborative agreement to sequence 5,000 cassava genotypes, ... wild species of the crop. Cassava is the ... developing countries (after maize, wheat and rice.) Results ...
... exploded in Yambuku, a remote village in Zaire, (now the ... Ebola had emerged, soon earning a grim distinction as one ... up to 90 percent of its victims, and producing a ... Charles Arntzen, a researcher at the Biodesign Institute at Arizona ...
Cached Biology News:Winning early-career researchers excel in entrepreneurship 2Winning early-career researchers excel in entrepreneurship 3BGI and CIAT announce collaboration for large-scale genome sequencing of cassava 2BGI and CIAT announce collaboration for large-scale genome sequencing of cassava 3Defensive measures: Toward a vaccine for Ebola 2Defensive measures: Toward a vaccine for Ebola 3Defensive measures: Toward a vaccine for Ebola 4Defensive measures: Toward a vaccine for Ebola 5
Mol wt: average mol wt16,951.27 Da by calculation...
... is the only PCR system that ensures ... time. It provides accuracy, consistency, and dependability ... the property of the DNA templates. This ... a unique blend of thermostable enzymes that ...
... C2C12 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... set-up Easy to assemble ... tubes, strips or Nunc 96 Well Amplifications ... tray can be fitted directly into the thermal cycler ... thermal cycler formats of major manufacturers Alphanumerically ...
Biology Products: